VA
GILD icon

Vident Advisory’s Gilead Sciences GILD Stock Holding History

Vident Advisory’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5M Buy
225,823
+63,326
+39% +$8.34M 0.21% 94
2026
Q1 		$22.6M Sell
162,497
-6,424
-4% -$900K 0.19% 102
2025
Q4 		$20.7M Buy
168,921
+24,832
+17% +$3.02M 0.19% 104
2025
Q3 		$16M Buy
144,089
+75,794
+111% +$8.62M 0.15% 127
2025
Q2 		$7.57M Buy
68,295
+28,788
+73% +$3.06M 0.09% 199
2025
Q1 		$4.43M Buy
39,507
+13,679
+53% +$1.41M 0.06% 263
2024
Q4 		$2.39M Sell
25,828
-29,112
-53% -$2.62M 0.04% 375
2024
Q3 		$4.61M Buy
54,940
+24,824
+82% +$1.89M 0.12% 166
2024
Q2 		$2.07M Sell
30,116
-9,748
-24% -$651K 0.06% 357
2024
Q1 		$2.92M Sell
39,864
-69,227
-63% -$5.32M 0.06% 301
2023
Q4 		$8.84M Buy
109,091
+1,266
+1% +$98.5K 0.22% 143
2023
Q3 		$8.08M Buy
+107,825
New +$8.29M 0.25% 131

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vident Advisory's GILD Position: Q2 2026 in Review

Vident Advisory increased its Gilead Sciences (GILD) stake by 39% in Q2 2026, buying an estimated $8.34M and bringing the position to 225,823 shares worth $28.5M. The position accounts for 0.21% of the portfolio, ranked #94.

Vident Advisory first reported a position in GILD in Q3 2023 and has held it in 12 quarters since. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Vident Advisory held 225,823 shares of Gilead Sciences worth $28.5M as of Q2 2026.
  • Vident Advisory bought 63,326 Gilead Sciences shares in Q2 2026, an estimated $8.34M.
  • Gilead Sciences made up 0.21% of Vident Advisory's portfolio in Q2 2026, its #94 holding.
  • Vident Advisory first reported a position in Gilead Sciences in Q3 2023 and has held it in 12 quarters since.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.